PTPRC and neoplasm: The extent of vessel perfusion, pericyte coating and inflammatory cell infiltration (that is, CD45, F4/80 and macrophage mannose receptor (MMR)-positive cells did, however, not differ between RIP1-TAg2:WT and RIP1-TAg2:Vegfr2Y949F/Y949F tumours at week 14 (Supplementary Fig. 3a–e).